Exciting News: Cancer Drug Resistance Journal’s New Impact Factor Reaches 4.6, Ranked in Q1 in Oncology!

We are pleased to announce that our journal, Cancer Drug Resistance (CDR), has obtained a new Impact Factor 2023 of 4.6, as reported by the Journal Citation Reports (JCR) released by Clarivate Analytics on June 20, 2024. Our journal is now ranked in the Q1 for Oncology! This accomplishment reflects our commitment to publishing high-quality scientific research results and underscores the significant impact of our journal in the field of cancer research.

The year 2024 marks a milestone for CDR. The Editorial Office would like to thank all our Editorial Board members, reviewers, authors, and readers for their ongoing support and trust. We look forward to working with more outstanding researchers to further advance cancer drug resistance research in the future and share more groundbreaking findings with the scientific community.

Together, we will continue to infuse CDR with vitality and contribute to the fight against cancer！

Editor: Hui Man
Language Editor: Catherine Yang
Production Editor: Yan Zhang
Respectfully submitted by the Editorial Office of Cancer Drug Resistance